Patents Assigned to Citryll B.V.
  • Publication number: 20250084154
    Abstract: The invention provides methods for the inhibition of Eosinophil Extracellular Trap (EET) formation. In particular, the invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes, for use in methods to inhibit or detect EET formation. The methods may be for the diagnosis, treatment or prevention of any disease or condition which includes an EET-associated pathology.
    Type: Application
    Filed: May 4, 2022
    Publication date: March 13, 2025
    Applicant: Citryll B.V.
    Inventors: Helmuth Hendrikus Gerardus VAN ES, Renato Gerardus Silvano CHIRIVI, Daphne MONTIZAAN, Eric Charles MELDRUM
  • Patent number: 11066462
    Abstract: The invention is in the field of methods and preparations for medical treatments, in particular the treatment of idiopathic pulmonary fibrosis (IPF). The invention provides such methods wherein antibodies or fragments thereof that react with selected citrullinated epitopes are used in the treatment of IPF. Antibodies against citrullinated epitopes situated at the amino terminus of histone polypeptides H2A and H4 were found to be particularly useful. The invention therefore relates to an antibody specifically reactive with a citrullinated epitope on the N-terminus of deiminated histone H2A or H4 for use in the prevention or treatment of idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: July 20, 2021
    Assignee: Citryll B.V.
    Inventors: Renato Gerardus Silvano Chirivi, Jozef Maria Hendrik Raats